MATERIALS AND METHODS
Patients. Sixty-three patients receiving gentamicin for various infections were studied. The patients were randomly divided into two groups. Groups 1 received gentamicin diluted in 100 ml of 5% glucose and water or saline and infused over approximately a 2-h period. Group 2 received gentamicin diluted in 50 ml of 5% glucose and water or saline and administered over 3 to 5 min using a Soluset system. The flow rate was monitored by a nurse assigned to this study.
Blood samples for gentamicin assay were drawn between days 3 and 5 of therapy on all except three patients. Group 1 was treated for a mean of 6.4 days and group 2 was treated for a mean of 6.1 days.
In the 63 patients studied, 7 received gentamicin only and 56 received gentamicin in addition to other antibiotics. Renal function studies (serum creatinine, blood urea nitrogen, and urinalysis with microscope examination of sediment) were performed before the initial dose of gentamicin and every third day of treatment.
In the present study, 49 of 57 patients with normal renal function before therapy was instituted received 120 mg/dose. Only eight with normal renal function received 60 to 100 mg/dose. Four of the six patients with impaired renal function received 60 to 80 mg/dose, one received 120 mg every 12 h, and one received 120 mg every 8 h. Six of the 63 patients in the present study had impaired renal function before gentamicin was started.
Audiology. All patients were tested, in their hospital rooms, with a portable MAICO H-I audiometer with TDH-39 earphones. The audiometer was calibrated before the onset of the investigation, and the calibration was checked biweekly thereafter.
At the onset of gentamicin therapy, each patient received a pure-tone audiogram at 250 to 8,000 Hz. All pure-tone averages were calculated for 500, 1,000, and 2,000 Hz on examination. Significant change in the audiogram was defined as one greater than 10 dB in pure-tone averages or pure-tone levels. Pure-tone audiometry was performed at the beginning, on the third day, and at the end of therapy.
Several patients were subsequently tested in a sound-proof room with a MAICO-24 audiometer, and the results did not differ significantly from those obtained with the portable audiometer used in the hospital rooms.
Vestibular function was checked daily during therapy; patients were questioned regarding dizziness, lightheadedness, and tinnitus and were examined when possible for evidence of nystagmus. .Electronystagmography was not performed.
Specimens. Blood samples for gentamicin assay were drawn between days 3 and 5 of therapy in all except three patients. For the 3-to 5-min slow-bolus method, a preinfusion sample was drawn, and samples were obtained at 1 to 2 min, 10 min, 1 h, and 8 h postinfusion. For the 2-h infusion method, a preinfusion sample was drawn, and samples were obtained 1 h intrainfusion. Upon completion of infusion, samples were drawn at 1 to 2 min, 1 h, and 6 h postinfusion. Blood samples were allowed to clot and the sera were frozen at -20 C until the assay.
Microbiological assay. Sera with gentamicin only were assayed in quadruplicate as described previously (7) . Sera containing gentamicin in addition to other antibiotics were assayed in a similar manner but with 1 8~~~~. inoculum in 50 ml of melted 1% Mueller-Hinton agar. The Serratia strain was resistant to the penicillins, lincomycin, erythromycin, cephalosporins, streptomycin, and sulfonamides and was sensitive to kanamycin, gentamicin, polymixin B, chloramphenicol, and tetracycline. Serratia plates were incubated for 18 to 20 h before zone diameters were measured. Enzymatic assay. Escherichia coli W 677/HJR66, a mutant bearing an R-factor for the enzyme gentamicin adenyl transferase (GAT), (kindly provided by M. Brazeau, H6pital Notre-Dame, Montr6al, Quebec) was grown in brain heart infusion broth (Difco Laboratories, Detroit, Mich.) containing 5 ,ug of gentamicin per ml (Schering Corp, Pte. Claire, Quebec), and the osmotic lysate was prepared essentially as described by Benveniste 1 ). The reaction mixture was incubated at 37 C for 20 min, and 50 ,ul was removed and pipetted onto a phosphocellulose paper disk (2-cm diameter, Whatman P-81). The disk was allowed to stand 1 min to absorb the basic antibiotic, dried for 5 min at 80 C, washed for 20 min in flowing distilled water to remove unbound radioactivity, and dried. Phosphocellulose-bound radioactivity was counted in a Nuclear-Chicago Unilux IIA liquid scintillation spectrophotometer and plotted against the concentration of the antibiotic standards.
Since the results of serum gentamicin levels measured by both the biological and enzymatic assays were similar, in this paper only the values obtained by the enzymatic assay are reported.
RESULTS
Patients receiving gentamicin by 2-h infusion method. Twenty-seven patients 17 to 84 years old were studied. There were 15 males and 12 females ( Table 1 ). All except 5 received 120 mg of gentamicin every 8 h. Peak serum gentamicin levels were noted at 2 h (Fig. 1) .
Only one patient, no. 11 (Table 1 ), had a peak serum level in excess of 10 ,ug/ml. In no instance was there evidence of ototoxicity as determined by audiological and vestibular monitoring, as was expected from the levels obtained. Nephrotoxicity was not observed. Three patients, no. 5, 7, and 17 (Table 1) , had impaired renal function at the onset, but there was no evidence of further deterioration after gentamicin therapy.
Patients receiving gentamicin by bolus infusion (3 to 5 min). Thirty-six patients 19 to 83 years old were studied. There was 20 males and 16 females (Table 2) ; all except 10 received 120 mg of gentamicin every 8 h. Peak serum gentamicin levels were observed at 2 min postinfusion (Fig. 2) . Only 6 patients, E, P, R, Da, Ia, and Q, had peak serum levels in excess of 10 ,ug/ml. In no instance was there evidence of ototoxicity as determined by audiological and vestibular monitoring. Nephrotoxicity after therapy was noted in one patient, Ga (Table 2) , and was minimal and appeared to be reversing itself. Three patients, C, S, and Q, had impaired renal function before the administration of gentamicin; after therapy there was no evidence of further impairment.
DISCUSSION
There has been recent discussion in the literature as to what are the "potentially" nephroand ototoxic serum levels of gentamicin (3). Hewitt (4) suggests that levels from 10 to 15 jug/ ml may be ototoxic but, in fact, no investigation has been carried out to demonstrate this conclusively. In spite of this, there has been general reluctance to administer gentamicin by the bolus method for fear of increased toxicity. One study by Korner (5) on the IV bolus administration of gentamicin demonstrated no toxicity, but another by Nielsen and Elb (8) showed possible nephrotoxicity. However, the dose of gentamicin used in both of these studies was less than that used in the present report. In one of the studies (5), the standard dosage was 80 mg three times daily, whereas in the other (8) the doses ranged from 2 to 4 mg/kg per day.
Audiological and renal function were followed in all patients before and after therapy, and in only one instance was there evidence of toxicity when the bolus method of infusion was compared to slow-infusion administration. Of ANTIMICROB. AGENTS CHEMOTHZR.
the six patients with impaired renal function, three received the drug by slow infusion and three received it by the bolus method. There was no evidence of ototoxicity or nephrotoxicity in any patient and, in fact, there was improvement in renal function in two. In one of these patients, Q (Table 2) , this occurred in spite of a peak serum gentamicin level in excess of 15 ,ug/ ml. In only one patient was there some deterioration ofrenal function (patient Ga), which was moderate. It is interesting that this patient's gentamicin serum levels were not in excess of 7.1 jug/ml.
The discouragingly low serum concentrations observed in the majority of patients 1 h after completion of the dose of gentamicin was reported previously (7) .
Based on these data, it may be concluded that the bolus administration of gentamicin is safe and nontoxic.
